Goldman Sachs’s Neos Therapeutics, Inc NEOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-337,188
| Closed | -$211K | – | 6551 |
|
|
2020
Q4 | $211K | Sell |
337,188
-2,294,397
| -87% | -$1.42M | ﹤0.01% | 5066 |
|
|
2020
Q3 | $1.4M | Sell |
2,631,585
-15,634
| -0.6% | -$10.6K | ﹤0.01% | 3836 |
|
|
2020
Q2 | $1.81M | Buy |
2,647,219
+55,147
| +2% | +$43.7K | ﹤0.01% | 3527 |
|
|
2020
Q1 | $1.94M | Buy |
2,592,072
+32,698
| +1% | +$44.9K | ﹤0.01% | 3327 |
|
|
2019
Q4 | $3.87M | Buy |
2,559,374
+135,859
| +6% | +$204K | ﹤0.01% | 3165 |
|
|
2019
Q3 | $3.59M | Sell |
2,423,515
-17,666
| -0.7% | -$28.6K | ﹤0.01% | 3102 |
|
|
2019
Q2 | $3.15M | Buy |
2,441,181
+1,207,167
| +98% | +$2.22M | ﹤0.01% | 3208 |
|
|
2019
Q1 | $3.22M | Buy |
1,234,014
+883,324
| +252% | +$2.07M | ﹤0.01% | 3302 |
|
|
2018
Q4 | $579K | Buy |
350,690
+319,636
| +1,029% | +$897K | ﹤0.01% | 4277 |
|
|
2018
Q3 | $151K | Sell |
31,054
-32,574
| -51% | -$185K | ﹤0.01% | 5000 |
|
|
2018
Q2 | $398K | Buy |
63,628
+30,493
| +92% | +$227K | ﹤0.01% | 4640 |
|
|
2018
Q1 | $275K | Sell |
33,135
-2,506
| -7% | -$23.9K | ﹤0.01% | 4826 |
|
|
2017
Q4 | $364K | Buy |
+35,641
| New | +$342K | ﹤0.01% | 5050 |
|
|
2016
Q4 | – | Sell |
-15,094
| Closed | -$99K | – | 7175 |
|
|
2016
Q3 | $99K | Buy |
15,094
+3,189
| +27% | +$25.3K | ﹤0.01% | 6230 |
|
|
2016
Q2 | $110K | Buy |
+11,905
| New | +$114K | ﹤0.01% | 6081 |
|
|
2015
Q4 | – | Sell |
-10,820
| Closed | -$227K | – | 7452 |
|
|
2015
Q3 | $227K | Buy |
+10,820
| New | +$238K | ﹤0.01% | 5892 |
|
Goldman Sachs's NEOS Position: Q1 2021 in Review
Goldman Sachs sold out of Neos Therapeutics, Inc (NEOS) in Q1 2021, closing a stake of 337,188 shares — an estimated $211K sold.
Goldman Sachs first reported a position in NEOS in Q3 2015 and held it in 16 quarters. The position peaked at $3.87M in Q4 2019. 0 funds tracked by Wall St. Rank hold NEOS as of Q1 2021.
- Goldman Sachs reported no remaining Neos Therapeutics, Inc position as of Q1 2021 after selling out during the quarter.
- Goldman Sachs sold 337,188 Neos Therapeutics, Inc shares in Q1 2021, an estimated $211K.
- Goldman Sachs first reported a position in Neos Therapeutics, Inc in Q3 2015 and held it in 16 quarters.
- Goldman Sachs's Neos Therapeutics, Inc position peaked at $3.87M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2021.
Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.